AN2 Therapeutics Inc (ANTX) stock analysis: A comprehensive overview

While AN2 Therapeutics Inc has underperformed by -9.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ANTX fell by -64.69%, with highs and lows ranging from $22.22 to $2.72, whereas the simple moving average fell by -73.09% in the last 200 days.

On April 02, 2024, JMP Securities Upgraded AN2 Therapeutics Inc (NASDAQ: ANTX) to Mkt Outperform. A report published by Leerink Partners on February 13, 2024, Downgraded its rating to ‘Market Perform’ for ANTX. Evercore ISI February 12, 2024d its ‘Outperform’ rating to ‘In-line’ for ANTX, as published in its report on February 12, 2024. JMP Securities’s report from January 04, 2024 suggests a price prediction of $30 for ANTX shares, giving the stock a ‘Mkt Outperform’ rating. Oppenheimer also rated the stock as ‘Outperform’.

3 Tiny Stocks Primed to Explode

The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Analysis of AN2 Therapeutics Inc (ANTX)

There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of AN2 Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -58.83% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.87, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

As an indicator of volatility for any stock, average volume can also be very valuable, and ANTX is recording an average volume of 422.84K. On a monthly basis, the volatility of the stock is set at 7.11%, whereas on a weekly basis, it is put at 8.92%, with a gain of 5.92% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.67, showing growth from the present price of $3.40, which can serve as yet another indication of whether ANTX is worth investing in or should be passed over.

How Do You Analyze AN2 Therapeutics Inc Shares?

Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 39.55%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 54.87% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

ANTX shares are owned by institutional investors to the tune of 54.87% at present.

Related Posts